4/1
07:18 am
ocgn
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease [Yahoo! Finance]
Medium
Report
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease [Yahoo! Finance]
4/1
07:16 am
ocgn
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease [TheStreet.com]
Low
Report
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease [TheStreet.com]
4/1
07:02 am
ocgn
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease
Low
Report
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease
3/31
03:45 am
ocgn
Ocugen (OCGN) Reveals OCU410 Clinical Trial Data [Yahoo! Finance]
Medium
Report
Ocugen (OCGN) Reveals OCU410 Clinical Trial Data [Yahoo! Finance]
3/28
08:33 pm
ocgn
How The Ocugen (OCGN) Narrative Is Shifting With Retinal Gene Therapy Data And New Valuations [Yahoo! Finance]
Medium
Report
How The Ocugen (OCGN) Narrative Is Shifting With Retinal Gene Therapy Data And New Valuations [Yahoo! Finance]
3/27
05:53 pm
ocgn
Ocugen Inc. (OCGN): One of the Popular Penny Stocks on Robinhood [Yahoo! Finance]
Medium
Report
Ocugen Inc. (OCGN): One of the Popular Penny Stocks on Robinhood [Yahoo! Finance]
3/25
02:37 pm
ocgn
Ocugen (OCGN) had its "buy" rating reaffirmed by Chardan Capital. They now have a $7.00 price target on the stock.
Low
Report
Ocugen (OCGN) had its "buy" rating reaffirmed by Chardan Capital. They now have a $7.00 price target on the stock.
3/25
08:03 am
ocgn
Ocugen (OCGN) had its price target raised by HC Wainwright from $7.00 to $10.00. They now have a "buy" rating on the stock.
Low
Report
Ocugen (OCGN) had its price target raised by HC Wainwright from $7.00 to $10.00. They now have a "buy" rating on the stock.
3/24
05:57 pm
ocgn
Ocugen (OCGN) Has A Healthy Cash Position For 2026 [Yahoo! Finance]
Low
Report
Ocugen (OCGN) Has A Healthy Cash Position For 2026 [Yahoo! Finance]
3/24
05:56 pm
ocgn
Ocugen, Inc. (OCGN) Discusses Top Line Results From Phase II ArMaDa Trial of OCU410 in Geographic Atrophy Transcript [Seeking Alpha]
Low
Report
Ocugen, Inc. (OCGN) Discusses Top Line Results From Phase II ArMaDa Trial of OCU410 in Geographic Atrophy Transcript [Seeking Alpha]
3/24
03:21 pm
ocgn
Ocugen Shares Phase II OCU410 Data Showing 31% Slower GA Lesion Growth at 12 Months [Yahoo! Finance]
Neutral
Report
Ocugen Shares Phase II OCU410 Data Showing 31% Slower GA Lesion Growth at 12 Months [Yahoo! Finance]
3/24
07:45 am
ocgn
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Medium
Report
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
3/24
02:35 am
ocgn
Is It Too Late To Consider Ocugen (OCGN) After Its Recent Share Price Surge [Yahoo! Finance]
Medium
Report
Is It Too Late To Consider Ocugen (OCGN) After Its Recent Share Price Surge [Yahoo! Finance]
3/23
12:46 pm
ocgn
Ocugen Index Addition Highlights Rising Attention And Ongoing Gene Therapy Risks [Yahoo! Finance]
Low
Report
Ocugen Index Addition Highlights Rising Attention And Ongoing Gene Therapy Risks [Yahoo! Finance]
3/23
07:20 am
ocgn
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy [Yahoo! Finance]
Low
Report
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy [Yahoo! Finance]
3/23
07:02 am
ocgn
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy
Low
Report
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy
3/21
02:17 am
ocgn
OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch [Yahoo! Finance]
Low
Report
OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch [Yahoo! Finance]
3/20
06:20 pm
ocgn
Oppenheimer Initiates Ocugen (OCGN) With a Buy Rating [Yahoo! Finance]
Low
Report
Oppenheimer Initiates Ocugen (OCGN) With a Buy Rating [Yahoo! Finance]
3/20
10:12 am
ocgn
OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development [Yahoo! Finance]
Low
Report
OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development [Yahoo! Finance]
3/17
09:00 am
ocgn
Ocugen (OCGN) is now covered by Canaccord Genuity Group Inc.. They set a "buy" rating and a $12.00 price target on the stock.
Low
Report
Ocugen (OCGN) is now covered by Canaccord Genuity Group Inc.. They set a "buy" rating and a $12.00 price target on the stock.
3/14
03:37 am
ocgn
Why Ocugen (OCGN) Is Up 54.0% After OCU400 Phase 3 Progress And Going Concern Spotlight [Yahoo! Finance]
Medium
Report
Why Ocugen (OCGN) Is Up 54.0% After OCU400 Phase 3 Progress And Going Concern Spotlight [Yahoo! Finance]
3/12
01:36 pm
ocgn
How Ocugen (OCGN) Phase 2 And Phase 3 Milestones Are Reframing The Investment Story [Yahoo! Finance]
Low
Report
How Ocugen (OCGN) Phase 2 And Phase 3 Milestones Are Reframing The Investment Story [Yahoo! Finance]
3/11
11:46 am
ocgn
Ocugen spikes as Oppenheimer issues new Outperform on upcoming catalysts [Seeking Alpha]
Medium
Report
Ocugen spikes as Oppenheimer issues new Outperform on upcoming catalysts [Seeking Alpha]
3/11
10:43 am
ocgn
Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline [Yahoo! Finance]
Low
Report
Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline [Yahoo! Finance]
3/11
08:03 am
ocgn
Ocugen (OCGN) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $10.00 price target on the stock.
High
Report
Ocugen (OCGN) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $10.00 price target on the stock.